KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Buy" from Analysts

Key Points

• KalVista Pharmaceuticals (NASDAQ:KALV) has received an average recommendation of "Buy" from nine analysts, with a 12 month price target averaging $26.43.
• In recent insider trading, CEO Benjamin L. Palleiko sold 32,979 shares at an average price of $15.69, which represented an 8.19% decrease in his ownership.
• KalVista reported a quarterly earnings loss of ($1.12) per share, missing analysts' estimates, while the company's revenue was $1.43 million, below the expected $1.97 million.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has received a consensus rating of "Buy" from the nine analysts that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $26.4286.

KALV has been the topic of several recent research reports. Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Leerink Partners raised their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. HC Wainwright raised their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. Finally, JMP Securities raised their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a "market outperform" rating in a research report on Friday, September 12th.

Insider Activity

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the transaction, the chief executive officer directly owned 369,595 shares in the company, valued at approximately $5,798,945.55. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Paul K. Audhya sold 2,942 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $38,893.24. Following the transaction, the insider owned 119,841 shares in the company, valued at approximately $1,584,298.02. This represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,835 shares of company stock worth $892,350. Corporate insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Ameriprise Financial Inc. bought a new position in KalVista Pharmaceuticals during the fourth quarter worth about $452,000. Bank of America Corp DE lifted its holdings in KalVista Pharmaceuticals by 108.8% during the fourth quarter. Bank of America Corp DE now owns 110,050 shares of the specialty pharmaceutical company's stock worth $932,000 after acquiring an additional 57,356 shares in the last quarter. Deutsche Bank AG lifted its holdings in KalVista Pharmaceuticals by 63.5% during the fourth quarter. Deutsche Bank AG now owns 35,841 shares of the specialty pharmaceutical company's stock worth $304,000 after acquiring an additional 13,923 shares in the last quarter. Graham Capital Management L.P. bought a new position in KalVista Pharmaceuticals during the fourth quarter worth about $89,000. Finally, ProShare Advisors LLC bought a new position in KalVista Pharmaceuticals during the fourth quarter worth about $101,000.

KalVista Pharmaceuticals Stock Performance

KALV traded up $0.50 during mid-day trading on Friday, reaching $13.88. The stock had a trading volume of 561,114 shares, compared to its average volume of 974,040. KalVista Pharmaceuticals has a 52 week low of $7.30 and a 52 week high of $17.28. The stock has a market capitalization of $701.22 million, a P/E ratio of -3.52 and a beta of -0.10. The firm's fifty day simple moving average is $14.00 and its two-hundred day simple moving average is $12.86.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.21). The firm had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.97 million. As a group, analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).